Correspondence 0001654954-23-005114 from ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682) (NDRA)
ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682)
Date: April 24, 2023 · CIK: 0001681682 · Accession: 0001654954-23-005114
AI Filing Summary & Sentiment
File numbers found in text: 333-271003
Letter
Re:
endra_coresp
April 24, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
ENDRA Life Sciences Inc.
Registration Statement on Form S-1
File No. No. 333-271003
Acceleration Request
Requested Date: April 26 2023
Requested Time: 4:30 p.m. Eastern Time (US)
Ladies and Gentlemen:
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as underwriter, hereby join in the request of ENDRA Life Sciences Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time (US), on April 26, 2023, or at such later time as the Company or its outside counsel, K&L Gates LLP, may request via a telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed approximately 450 copies of the Preliminary Prospectus dated April 18, 2023 through the date hereof, to underwriters, dealers, institutions and others.
The undersigned, as underwriter, has complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very
truly yours,
Acting
on behalf of itself and the several Underwriters
Show Raw Text
CORRESP 1 filename1.htm endra_coresp April 24, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ENDRA Life Sciences Inc. Registration Statement on Form S-1 File No. No. 333-271003 Acceleration Request Requested Date: April 26 2023 Requested Time: 4:30 p.m. Eastern Time (US) Ladies and Gentlemen: In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as underwriter, hereby join in the request of ENDRA Life Sciences Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time (US), on April 26, 2023, or at such later time as the Company or its outside counsel, K&L Gates LLP, may request via a telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed approximately 450 copies of the Preliminary Prospectus dated April 18, 2023 through the date hereof, to underwriters, dealers, institutions and others. The undersigned, as underwriter, has complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, Acting on behalf of itself and the several Underwriters NEWBRIDGE SECURITIES CORPORATION By: /s/ Chad D. Champion Name: Chad D. Champion Title: Senior Managing Director